$AGEN News

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Agenus to Provide Third Quarter 2026 Financial Report and Development Update

Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer

Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026

Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - But Caution Advised

Agenus: Hot Times As It Trudges Towards BOT/BAL Submission

Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19

Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing

Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40

Agenus Inc. (AGEN) Shareholder/Analyst Call - Slideshow

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Participate in Upcoming September Investor Conferences

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism